Next generation automation for Medical Writers to streamline the creation of regulatory documents
Certara is excited to announce that SynchrogenixTM Writer is the latest Certara software to incorporate powerful deep learning capabilities. AI is now woven seamlessly into Sychrogenix Writer’s medical writing process, ushering in the next generation of regulatory document creation. This upgrade supports medical writers with the automation needed in order to focus on key messaging and compliant documentation.
Built by Certara and born from this unmet need, Synchrogenix Writer includes everything from eTemplates and structured component authoring. The inclusion of Deep Learning (AI) technology is designed to streamline the submission process by allowing medical writers to apply automation capabilities at the right place and at the right time.
“AI and GPTs are making headlines in today’s news, and we are proud to be at the forefront of this technology, offering software that creates value for writers in the medical space” commented Leif E. Pederson, President of Software at Certara. “We continue to develop our technology in order to help researchers, medical writers, and all involved in the regulatory approval process stay compliant and organized, but also to make the daunting task easier!”
Certara’s Synchrogenix Writer enables medical writers to access deep learning technology (AI) in a trusted, secure, and efficient system designed and built for the drug discovery community. To learn more about Synchrogenix Writer, visit www.certara.com/synchrogenix-writer or join us at DIA Global 2023 where our experts will present Evolution of Submissions & Technology from 1983-2063.
Certara（サターラ）について
サターラは、独自のバイオシミュレーションソフトウェア、技術、サービスを用いて医薬品開発を加速し、従来の創薬・医薬品開発を変革します。製薬、教育機関、規制当局のお客様 2,000人以上、6262ヵ国にてサターラの技術やサービスが活用されています。
